Legato Capital Management LLC Purchases Shares of 10,314 scPharmaceuticals Inc. (NASDAQ:SCPH)

Legato Capital Management LLC purchased a new stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,314 shares of the company’s stock, valued at approximately $37,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of SCPH. Rice Hall James & Associates LLC raised its position in scPharmaceuticals by 25.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 621,665 shares of the company’s stock valued at $2,835,000 after purchasing an additional 124,438 shares during the last quarter. Thrivent Financial for Lutherans raised its position in scPharmaceuticals by 1.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after purchasing an additional 14,866 shares during the last quarter. King Luther Capital Management Corp raised its position in scPharmaceuticals by 0.9% during the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after purchasing an additional 20,650 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of scPharmaceuticals in the 3rd quarter worth approximately $57,000. Finally, BNP Paribas Financial Markets raised its position in shares of scPharmaceuticals by 116.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock worth $26,000 after acquiring an additional 3,101 shares in the last quarter. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH opened at $3.68 on Friday. scPharmaceuticals Inc. has a 52-week low of $3.08 and a 52-week high of $6.54. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. The firm has a market capitalization of $184.15 million, a P/E ratio of -1.94 and a beta of 0.11. The stock has a 50 day moving average price of $3.39 and a 200-day moving average price of $4.08.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Craig Hallum decreased their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research report on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.